CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy

Diana M. Escolar, Gunnar Buyse, Erik Henricson, Robert Leshner, Julaine Florence, Jill Mayhew, Carolina Tesi-Rocha, Ksenija Gorni, Livia Pasquali, Kantilal M. Patel, Robert McCarter, Jennifer Huang, Thomas Mayhew, Tulio Bertorini, Jose Carlo, Anne M. Connolly, Paula R. Clemens, Nathalie Goemans, Susan T. Iannaccone, Masanori IgarashiYoram Nevo, Alan Pestronk, S. H. Subramony, V. V. Vedanarayanan, Henry Wessel

Research output: Contribution to journalArticlepeer-review

82 Scopus citations


We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, doubleblind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.

Original languageEnglish (US)
Pages (from-to)151-155
Number of pages5
JournalAnnals of Neurology
Issue number1
StatePublished - Jul 2005

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this